Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Efrotomycin is a kirromycin-like antibiotic produced by Streptomyces lactamodurans (also referred to as Nocardia lacamduranns in some sources). It is primarily used in animal agriculture, especially for swine and poultry, where it serves as a feed additive to promote growth and improve feed efficiency. The drug consists of several components (Efrotomycin A1, A2, B1, B2) and has a narrow antibacterial spectrum. Its main mechanism of action is the inhibition of bacterial protein synthesis by targeting elongation factor Tu (EF-Tu), thereby interfering with peptide transfer reactions essential for bacterial growth. Efrotomycin shows activity mainly against certain Gram-negative bacteria such as Escherichia coli but limited or no activity against most Gram-positive bacteria like Bacillus subtilis. It was marketed under the brand name Producil for use in livestock feeds[1][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on efrotomycin.